DAX24.483 +0,5%Est505.795 +0,8%MSCI World4.343 -0,1%Top 10 Crypto11,60 -0,7%Nas23.474 -0,5%Bitcoin74.703 +0,9%Euro1,1766 -0,1%Öl62,13 +0,6%Gold4.401 +1,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 DroneShield A2DMAA Deutsche Telekom 555750 Novo Nordisk A3EU6F Bayer BAY001 BYD A0M4W9 Lufthansa 823212 Tesla A1CX3T Siemens Energy ENER6Y BASF BASF11 RENK RENK73 Mercedes-Benz Group (ex Daimler) 710000 Allianz 840400 Nike 866993
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX im Plus -- Rheinmetall, RENK, HENSOLDT & TKMS im Blick: Putin informiert Trump über angeblichen Angriff durch Kiew -- TUI, Palantir, Meta im Fokus
Top News
SoftBank-Aktie vor neuem Kapitel - Aktiensplit tritt in Kraft, KI bleibt Wachstumstreiber SoftBank-Aktie vor neuem Kapitel - Aktiensplit tritt in Kraft, KI bleibt Wachstumstreiber
Vor Silvesterpause: DAX zeigt sich im verkürzten Dienstagshandel freundlich Vor Silvesterpause: DAX zeigt sich im verkürzten Dienstagshandel freundlich
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Icecure Medical Aktie

Kaufen
Verkaufen
0,6551 USD -0,0093 USD -1,40 %
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.38,79 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1W1LG

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINIL0011224156

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolICCM

Icecure Medical Aktien News

DatumMeistgelesen
PR NewswireIceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer
PR NewswireIceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting
PR NewswireIceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes
PR NewswireIceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
PR NewswireIceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer
PR NewswireIceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
PR NewswireIceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025
PR NewswireIceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction
PR NewswireIceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival
PR NewswireIceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances
PR NewswireIceCure Medical to Attend the 2025 Maxim Growth Summit
PR NewswireIceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented
PR NewswireIceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented
PR NewswireIceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes
PR NewswireIceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications
PR NewswireTwo New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highes...
PR NewswireIceCure Reports Financial & Operational Results for the First Half of 2025
PR NewswireIceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025
PR NewswireIceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
PR NewswireIceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025
PR NewswireIceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes
PR NewswireIceCure Medical Reports First Quarter 2025 Financial Results
PR NewswireIceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025
PR NewswireIceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation
PR NewswireIceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America
PR NewswireIceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate
PR NewswireIceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025
PR NewswireIceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer
PR NewswireIceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference
PR NewswireIceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology
PR NewswireIceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel
PR NewswireIceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipat...
PR NewswireIceCure Files for Regulatory Approval of ProSense® Cryoablation System in China
PR NewswireIceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America
PR NewswireIceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule
PR NewswireEuropean Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology
PR NewswireData on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting
PR NewswireIceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results
PR NewswireIceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation
PR NewswireIceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office

Icecure Medical News

Icecure Medical News: auf dieser Seite finden Sie alle Icecure Medical News und Nachrichten zur Icecure Medical Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Icecure Medical News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Icecure Medical News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.